Kura Oncology, Inc. (KURA) vs MoonLake Immunotherapeutics (MLTX)
Kura Oncology, Inc. and MoonLake Immunotherapeutics are both Biotechnology companies. Kura Oncology, Inc. and MoonLake Immunotherapeutics are of similar size ($1.0B and $977.7M). MoonLake Immunotherapeutics has the higher net margin (0.00% vs −384.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, MoonLake Immunotherapeutics leads on 7 and Kura Oncology, Inc. on 6.
Valuation
Profitability
| Metric | KURA | MLTX | Biotechnology median |
|---|---|---|---|
| Gross margin | 99.35% | 0.00% | 65.16% |
| Operating margin | (411.90%) | 0.00% | 0.00% |
| Net margin | (384.30%) | 0.00% | 0.00% |
| Free cash flow margin | (152.06%) | 0.00% | 0.00% |
| Return on equity | (167.71%) | (67.08%) | (57.72%) |
| Return on assets | (46.73%) | (51.00%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack